Medlab Clinical (MDC) Stock Price, News & Analysis

Company Overview

Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia. Its drug candidate includes NanaBis, a buccal spray from cannabis oil extract for oncology and pain management; and NanoCBD, a buccal spray from hemp oil extract for mental health. The company also develops NanoCelle, a patented sub-micron drug delivery platform that allows passive diffusion of active pharmaceutical ingredients directly into the bloodstream through oral-buccal, sublingual, intranasal, and transdermal or topical delivery. In addition, it offers virtual clinic services. The company was founded in 2012 and is headquartered in Botany, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 36,677 shs
• Average Volume: N/A
• Market Capitalization: $15.07 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MDC Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Medlab Clinical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Medlab Clinical investors own include Magellan Financial Group (MFG), iSignthis (ISX), FBR (FBR), Embark Early Education (EVO), Dacian Gold (DCN), Constellation Technologies (CT1) and Bod Australia (BDA).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Construction
• Current Symbol: ASX:MDC
• CIK: N/A
• Web: www.medlab.co
• Phone: 61 2 8188 0311
• Fax: N/A
• Employees: 1,640
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): A($547.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.94 million
• Net Margins: -1,351.41%
• Pretax Margin: N/A
• Return on Equity: 12,575.02%
• Return on Assets: -79.67%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.35
• Quick Ratio: 3.71

Sales & Book Value

• Annual Sales: -$1.47 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 5.12
• Book Value: A($0.31) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 2,280,000
• Free Float: N/A
• Market Cap: $15.07 million
• Optionable: Not Optionable
• Beta: 0.89